表紙
市場調查報告書

傳染病分子診斷市場:自定義類型的預測□分析 (綜合症候群區別□複合體區別□診斷場所區別□國家別)、新冠病毒 (Covid-19)感染的影響、對高管的建議 (2020∼2024年)

Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2020 - 2024

出版商 Howe Sound Research 商品編碼 939946
出版日期 內容資訊 英文 454 Pages
商品交期: 最快1-2個工作天內
價格
傳染病分子診斷市場:自定義類型的預測□分析 (綜合症候群區別□複合體區別□診斷場所區別□國家別)、新冠病毒 (Covid-19)感染的影響、對高管的建議 (2020∼2024年) Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2020 - 2024
出版日期: 2020年06月01日內容資訊: 英文 454 Pages
簡介

受新型冠狀病毒感染(Covid-19)傳播的影響,世界各地對傳染病的分子診斷的需求正在迅速增長。當多重方法成為常態時,只依賴微生物診斷法則正在減少。

本報告是針對傳染病分子診斷未來的技術進步□市場成長的預估與分析,包含技術性的概要與主要應用類別、對未來的醫療影響力、至今為止的主要開發與商品上市的動向、主要企業介紹與主要產品、未來市場規模的動向與預測、地區別□綜合症候群區別□複合體區別□診斷場所區別的詳細動向、新型冠狀病毒(Covid-19)發生的影響,等資訊綜合分析而成。

目錄

i. 傳染病分子診斷市場:戰略狀況分析與Covid-19的影響

ii. 執行概要□市場□銷售□給商業開發人員的建議

iii. 給經營顧問□投資顧問的建議

第1章 導論、市場定義

第2章 傳染病:根據病症的市場分析

  • HIV-人類免疫缺陷病毒(AIDS)
    • 病因、流行病學
    • 診斷□檢查方法
    • 市場機會分析
  • HBV-B型肝炎
  • HCV-C型肝炎
  • HPV-人乳頭瘤病毒
  • 流感
  • CTGC-衣原體/淋病
  • 結核
  • MRSA-耐甲氧西林金黃色葡萄球菌
  • VRE-耐萬古黴素的腸球菌
  • 血液篩查
  • 新型冠狀病毒 (Covid-19)
  • 大流行診斷

第3章 業界概要

  • 主要參與市場的公司
    • 教育□研究機構
    • 開發診斷檢查的公司
    • 測量儀器供應商
    • 試劑分銷商□供應商
    • 獨立實驗檢查室
    • 國營/公營實驗檢查室
    • 醫院內實驗檢查室
    • 個人開業醫生
    • 監察機構
    • 認證機構
  • 臨床實驗室分類
    • 至今的市場區分
    • 實驗檢查室的重點與區分
  • 產業結構
    • 醫院的檢查份額
    • 經濟規模
    • 個人開業醫生
    • 醫生與POCT
  • 主要分子診斷公司概要
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMérieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • 榮研化學
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

第4章 市場動向

  • 市場成長的正面因素
  • 市場成長的負面因素
  • 儀表與自動化
  • 診斷技術與動向
    • 敗血症測試市場-新的方向性?
    • 作為創造性破壞的因素POCT /自行檢查
    • 遺傳學的玩笑-所有已知傳染病的檢測方法
    • 抗生素抗性基因-簡化診斷

第5章 傳染病分子診斷:至今為止的進展

  • 本節的重要性及其使用方法

第6章 全球的世界傳染病分子診斷市場

  • 國別分析:概要
  • 綜合症候群區別分析:概要
  • 通過plex分析(擴增方法):概要
  • 診斷場所區別分析:概要

第7章 全球的世界傳染病分子診斷市場:綜合症候群區別

  • 呼吸系統
  • 胃腸
  • 血液
  • 腦膜炎/腦炎
  • 性病
  • 其他

第8章 全球的世界傳染病分子診斷市場:plex分析

  • 單叢
  • 複式
  • 三層
  • 多重

第9章 全球的世界傳染病分子診斷市場:診斷場所

  • 院內檢查實驗室
  • 院外檢查實驗室
  • POC (護理站) 診斷
  • 其他

附錄

目錄

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

  • Multiplex testing
  • pathogen evolution and pandemics
  • biotechnology advances in genetics
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19.

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenues
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease

  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
    • 2.1.4 Market Opportunity Analysis
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
    • 2.3.2 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 Blood Screening
    • 2.10.1 Collection and Testing
    • 2.10.2 FDA Approved Multiplex Assays
    • 2.10.3 Market Opportunity Analysis
  • 2.11 COVID-19
    • 2.11.1 Signs and symptoms
    • 2.11.2 Transmission
    • 2.11.3 Diagnosis
    • 2.11.4 Prevention
    • 2.11.5 Management
    • 2.11.6 Prognosis
  • 2.12 Pandemic Diagnostics
    • 2.12.1 Risk Management - Spark and Spread
    • 2.12.2 Dx Technology - Nucleic Acid Based
    • 2.12.3 Dx Technology - Immunoassay & Serology
    • 2.12.4 Time to Market and Preparedness Issues
    • 2.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Industry Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Distributor and Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Office Labs
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
      • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT
  • 3.4 Profiles of Key MDx Companies
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Atlas Genetics
    • Aus Diagnostics
    • BD Diagnostics
    • Beckman Coulter
    • Biocartis
    • bioMérieux
    • Bio-Rad Laboratories
    • Bosch Healthcare Solutions GmbH
    • Cepheid
    • Chembio
    • Curetis
    • Diagenode Diagnostics
    • DiaSorin
    • Eiken Chemical
    • Fusion Genomics.
    • Genedrive
    • GenePOC Diagnostics
    • GenMark Dx
    • Grifols
    • Hologic
    • Illumina
    • Inflammatix
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • Luminex
    • Mbio Diagnostics
    • Meridian Bioscience
    • Mesa Biotech
    • Mobidiag
    • Nanomix
    • Oxford Nanopore Technologies
    • Panagene
    • Primerdesign
    • Prominex
    • Qiagen
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Seegene
    • Siemens Healthineers
    • T2 Biosystems
    • Thermo Fisher
    • Veramarx
    • XCR Diagnostics

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 New Genotypes Creating New Markets
    • 4.1.2 Aging Population a Boon for All Diagnostics
    • 4.1.3 Developing World Driving ID Dx Growth
    • 4.1.4 Point of Care - Why Centralization is Losing Steam
    • 4.1.5 Self Testing
    • 4.1.6 The Need for Speed
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Costs
    • 4.2.2 Infectious Disease is Declining
    • 4.2.3 Wellness Hurts
    • 4.2.4 Economic Growth improves Living Standards
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.2 Multiplex, Point of Care and The Speed Factor
  • 4.4 Diagnostic Technology Development
    • 4.4.1 The Sepsis Testing Market - A New Direction?
    • 4.4.2 POCT/Self Testing as a Disruptive Force
    • 4.4.3 The Genetics Play - One Test for All Known Infections
    • 4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • Lumos Diagnostics Closes $15M Series A Funding
  • Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
  • New Genomic Tests Diagnose Deadly Infections Faster
  • Biotia Raises $2.4M Seed Round
  • STDs resurge in US
  • Ares Genetics signs R&D agreement with leading global IVD corporation
  • Cell-Free DNA Used for Infectious Disease Testing
  • One BioMed Raises $5M
  • FDA grants Qiagen clearance for syndromic testing system
  • iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays
  • Researchers Launch CRISPR Dx Firm Sherlock Biosciences
  • Israel's BATM to Invest up to $30M in Ador Diagnostics
  • Superbug Test from Mobidiag Gets CE Mark
  • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • Mesa Biotech RSV Test Wins CE Mark
  • Karius Test to Be Available in Brazil
  • Panagene's STD kit gains Approval
  • Startup Prominex Raises $4M in Series A1
  • GenePOC's Investment Validated by Medicare Decision
  • GenePOC® launches its GenePOC® CDiff test in Canada
  • NYU researchers adapt HIV test to Zika virus
  • GA-EMS receives diagnostic device contract
  • Biocartis & Immunexpress Sign Partnership for Sepsis
  • PerkinElmer to Acquire Euroimmun for $1.3B
  • Alveo Closes Financing to Create Accessible Diagnostics Devices
  • Siemens Healthineers completes takeover of Fast Track Diagnostics
  • Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
  • Chembio and FIND to Develop Point-of-Care Multiplex Test
  • Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
  • Alere bags FDA nod for rapid flu diagnostic
  • FDA approves tests of tick-borne disease to protect blood supply
  • Qiagen Trichomonas Assay Gets CE Mark
  • Vela Diagnostics HSV Test Gets FDA Clearance
  • QIAGEN enters into agreement to acquire STAT-Dx
  • Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
  • Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
  • Ares Genetics to develop AI diagnostic test for infectious diseases
  • FDA Considers Guidelines for NGS-Based Infectious Disease Diagnostics

6. The Global Market for Molecular Diagnostics Infectious Disease

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Syndrome - Overview
    • 6.2.1 Table - Global Market by Syndrome
    • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Syndrome - Base Year
    • 6.2.4 Chart - Global Market by Syndrome - End Year
    • 6.2.5 Chart - Global Market by Syndrome - Share by Year
    • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 6.3 Global Market by Plex - Overview
    • 6.3.1 Table - Global Market by Plex
    • 6.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Plex - Base Year
    • 6.3.4 Chart - Global Market by Plex - End Year
    • 6.3.5 Chart - Global Market by Plex - Share by Year
    • 6.3.6 Chart - Global Market by Plex - Segments Growth
  • 6.4 Global Market by Place - Overview
    • 6.4.1 Table - Global Market by Place
    • 6.4.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 6.4.3 Chart - Global Market by Place - Base Year
    • 6.4.4 Chart - Global Market by Place - End Year
    • 6.4.5 Chart - Global Market by Place - Share by Year
    • 6.4.6 Chart - Global Market by Place - Segments Growth

7. Global MDx Infectious Disease Markets - By Syndrome

  • 7.1 Respiratory
    • 7.1.1 Table Respiratory - by Country
    • 7.1.2 Chart - Respiratory Growth
  • 7.2 Gastrointestinal
    • 7.2.1 Table Gastrointestinal - by Country
    • 7.2.2 Chart - Gastrointestinal Growth
  • 7.3 Blood
    • 7.3.1 Table Blood - by Country
    • 7.3.2 Chart - Blood Growth
  • 7.4 Meningitis/Encephalitis
    • 7.4.1 Table Meningitis/Encephalitis - by Country
    • 7.4.2 Chart - Meningitis/Encephalitis Growth
  • 7.5 Sexually Transmitted Disease
    • 7.5.1 Table Sexually Transmitted Disease - by Country
    • 7.5.2 Chart - Sexually Transmitted Disease Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global MDx Markets for Infectious Disease - by Plex

  • 8.1 Single Plex
    • 8.1.1 Table Single Plex - by Country
    • 8.1.2 Chart - Single Plex Growth
  • 8.2 Duplex
    • 8.2.1 Table Duplex - by Country
    • 8.2.2 Chart - Duplex Growth
  • 8.3 Triplex
    • 8.3.1 Table Triplex - by Country
    • 8.3.2 Chart - Triplex Growth
  • 8.4 Multiplex Technology
    • 8.4.1 Table Multiplex - by Country
    • 8.4.2 Chart - Multiplex Growth

9. Global MDx Infectious Disease Markets - by Place

  • 9.1 Hospital Lab
    • 9.1.1 Table Hospital Lab - by Country
    • 9.1.2 Chart - Hospital Lab Growth
  • 9.2 Outpatient Lab
    • 9.2.1 Table Outpatient Lab - by Country
    • 9.2.2 Chart - Outpatient Lab Growth
  • 9.3 POC
    • 9.3.1 Table POC - by Country
    • 9.3.2 Chart - POC Growth
  • 9.4 Other Technology
    • 9.4.1 Table Other - by Country
    • 9.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Classification of HIV Species
  • Table 3 HIV Tests - CMS Codes & Prices
  • Table 4 Current HIV Molecular Tests and Instruments Used
  • Table 5 HBV Tests - CMS Codes & Prices
  • Table 6 HCV Tests - CMS Codes & Prices
  • Table 7 HPV Clearance Rates
  • Table 8 HPV Tests - CMS Codes & Prices
  • Table 9 HPV Tests, Technology, Types
  • Table 10 Types of Influenza Tests
  • Table 11 Influenza Tests - CMS Codes & Prices
  • Table 12 FDA Cleared Molecular Assays for Influenza
  • Table 13 FDA Cleared NAAT CTGC Tests
  • Table 14 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 15 CTGC Tests - CMS Codes & Prices
  • Table 16 FDA Approved MDx Tests for Tuberculosis
  • Table 17 Tuberculosis Tests - CMS Codes & Prices
  • Table 18 FDA Approved Tests for MRSA
  • Table 19 MRSA Tests - CMS Codes & Prices
  • Table 20 FDA Approved Tests for VRE
  • Table 21 VRE Tests - CMS Codes & Prices
  • Table 22 FDA Approved Multiplex Assays
  • Table 23 Characteristics of Coronavirus Pandemic Infections
  • Table 24 COVID-19 Symptoms
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Five Factors Driving Growth
  • Table 30 Four Factors Limiting Growth
  • Table 31 Key Diagnostic Laboratory Technology Trends
  • Table 32 - Global Market by Region
  • Table 33 Global Market by Syndrome
  • Table 34 Global Market by Plex
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Single Plex by Country
  • Table 43 Duplex by Country
  • Table 44 Triplex by Country
  • Table 45 Multiplex by Country
  • Table 46 Hospital Lab by Country
  • Table 47 Outpatient Lab by Country
  • Table 48 POC by Country
  • Table 49 Other by Country
  • Table 50 2020 Clinical Lab Fee Schedule
  • Table 51 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 HIV Virion
  • Figure 3 Diagram of the HIV Replication Cycle
  • Figure 4 The Structure of the HBV Virus
  • Figure 5 Hepatitis B Replication
  • Figure 6 Structure of the HCV Virus
  • Figure 7 HCV Replication Cycle
  • Figure 8 Structure of the Influenza Virion
  • Figure 9 Influenza Replication
  • Figure 10 Scanning Electronmicrograph of Tuberculosis
  • Figure 11 Percentage of World Population Over 65
  • Figure 12 Chart Infectious Disease Decline
  • Figure 13 Global Market Density Chart
  • Figure 14 Global Market by Syndrome - Base vs. Final
  • Figure 15 Global Market by Syndrome Base Year
  • Figure 16 Global Market by Syndrome End Year
  • Figure 17 Syndrome Share by Year
  • Figure 18 Syndrome Segments Growth
  • Figure 19 Global Market by Plex - Base vs. Final
  • Figure 20 Global Market by Plex Base Year
  • Figure 21 Global Market by Plex End Year
  • Figure 22 Plex Share by Year
  • Figure 23 Plex Segments Growth
  • Figure 24 Global Market by Place - Base vs. Final
  • Figure 25 Global Market by Place Base Year
  • Figure 26 Global Market by Place End Year
  • Figure 27 Place Share by Year
  • Figure 28 Place Segments Growth
  • Figure 29 Respiratory Growth
  • Figure 30 Gastrointestinal Diagnostics Growth
  • Figure 31 Blood Growth
  • Figure 32 Meningitis/Encephalitis Growth
  • Figure 33 Sexually Transmitted Disease Growth
  • Figure 34 Other Growth
  • Figure 35 Single Plex Growth
  • Figure 36 Duplex Growth
  • Figure 37 Triplex Growth
  • Figure 38 Multiplex Growth
  • Figure 39 Hospital Lab Growth
  • Figure 40 Outpatient Lab Growth
  • Figure 41 POC Growth
  • Figure 42 Other Growth